mesenchymal markers

[Oncogenesis] A mutation in isocitrate dehydrogenase 1 was found to suppress the transforming growth factor-beta signaling pathway and E2F4 interacted with Smad3 to inhibit expression of mesenchymal markers.

[Scientific Reports] Researchers investigated a novel compound, 3-acetyl-5,8-dichloro-2-((2,4-dichlorophenyl)amino)quinolin-4(1H)-one (ADQ), that showed significant suppression of wound healing and cellular invasion. This compound also inhibited anchorage-independent cell growth, multicellular tumor spheroid survival/invasion, and metalloprotease activities.

[Oncogene] Researchers reported that the expression of CRYβB2 in breast cancer cells increased stemness, growth, and metastasis. Transcriptomics data revealed that CRYβB2 upregulated genes that were functionally associated with unfolded protein response, oxidative phosphorylation, and DNA repair, while down-regulating genes related to apoptosis.

[Oncology Reports] Scientists revealed that TβRI‑TβRII‑Fc chimeric receptor suppressed the epithelial‑mesenchymal transition program in melanoma cells in vitro induced by any of the three TGF‑β isoforms, as revealed by decreased expression of mesenchymal markers.

[Oncogene] Investigators demonstrated that ZEB2, the transcription factor of epithelial–mesenchymal transition, was upregulated in ascites cells from high-grade serous ovarian cancer patients and in CD133+ cancer stem-like cells from epithelial ovarian cancer cell lines.

[Oncogenesis] Investigators found that in KrasG12D-expressing endometrial organoids, Pten knockdown did not confer tumorigenicity, but Cdkn2a knockdown or Trp53 deletion led to the development of carcinosarcoma, a rare, aggressive tumor comprising both carcinoma and sarcoma.